Polaris Group (United States)

Recent papers from Polaris Group (United States)

1. BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced ApoptosisClinical Cancer Research · 2025
2. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the MicroenvironmentClinical Cancer Research · 2023
3. Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemiaCancer Medicine · 2021
4. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia PatientsScientific Reports · 2017
5. A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomasCell Death and Disease · 2016
6. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatinOncotarget · 2015
7. Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomasThe Journal of Pathology Clinical Research · 2014
8. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosisCell Death and Disease · 2012
9. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminaseBritish Journal of Cancer · 2012
10. Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest ¹⁸F-FDG Is Not Suitable to Evaluate Clinical Response in MelanomaJournal of Nuclear Medicine · 2012
11. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetaseBritish Journal of Cancer · 2011